Literature DB >> 18836468

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

M Campoli1, S Ferrone.   

Abstract

Changes in classical and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesions. These changes, which are described in this review are believed to play a major role in the clinical course of the disease since both HLA class I and class II antigens are critical to the interaction between tumor cells and components of both innate and adaptive immune system. Abnormalities in HLA antigen expression in malignant cells, which range in frequency from 0-90%, are caused by distinct mechanisms. They include defects in beta(2)-microglobulin (beta(2)m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, defects in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or more of the antigen processing, machinery (APM) components. More recently, epigenetic events associated with tumor development and progression have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and tumor antigen (TA) expression in malignant cells. The types of epigenetic modifications that may occur in normal and malignant cells as well as their role in changes in HLA antigen expression by malignant cells have been reviewed. The epigenetic events associated with alterations in HLA antigen expression may be clinically relevant as, in some cases, they have been shown to impair the recognition of tumor cells by components of the adaptive immune system. The functional relevance and potential clinical significance of these epigenetic alterations have been addressed. Finally, unlike genetic alterations, epigenetic modifications can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. Therefore, strategies to overcome epigenetic modifications underlying changes in HLA antigen expression in malignant cells have been discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836468      PMCID: PMC2729106          DOI: 10.1038/onc.2008.273

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  130 in total

Review 1.  Histone lysine methylation: a signature for chromatin function.

Authors:  Robert J Sims; Kenichi Nishioka; Danny Reinberg
Journal:  Trends Genet       Date:  2003-11       Impact factor: 11.639

Review 2.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

3.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Authors:  P Wijermans; M Lübbert; G Verhoef; A Bosly; C Ravoet; M Andre; A Ferrant
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

4.  Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.

Authors:  Francesco Lozupone; Licia Rivoltini; Francesca Luciani; Massimo Venditti; Luana Lugini; Agata Cova; Paolo Squarcina; Giorgio Parmiani; Filippo Belardelli; Stefano Fais
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

Review 5.  Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.

Authors:  Nathalie Rouas-Freiss; Philippe Moreau; Catherine Menier; Joël LeMaoult; Edgardo D Carosella
Journal:  Semin Cancer Biol       Date:  2007-07-17       Impact factor: 15.707

Review 6.  Molecular mechanisms of MHC class I abnormalities and APM components in human tumors.

Authors:  Barbara Seliger
Journal:  Cancer Immunol Immunother       Date:  2008-04-12       Impact factor: 6.968

7.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.

Authors:  A Nazmul H Khan; Christopher J Gregorie; Thomas B Tomasi
Journal:  Cancer Immunol Immunother       Date:  2007-11-28       Impact factor: 6.968

8.  Expression and regulation of non-classical HLA-G in renal cell carcinoma.

Authors:  K Dunker; G Schlaf; J Bukur; W W Altermann; D Handke; B Seliger
Journal:  Tissue Antigens       Date:  2008-08

Review 9.  Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?

Authors:  Maresa Altomonte; Ester Fonsatti; Alberto Visintin; Michele Maio
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

Review 10.  The role of HLA-G in human pregnancy.

Authors:  Joan S Hunt; Daudi K Langat; Ramsey H McIntire; Pedro J Morales
Journal:  Reprod Biol Endocrinol       Date:  2006       Impact factor: 5.211

View more
  158 in total

1.  A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.

Authors:  Alexander K Tsai; Asra Y Khan; Christina E Worgo; Lucy L Wang; Yuanyuan Liang; Eduardo Davila
Journal:  Cancer Immunol Res       Date:  2017-08-03       Impact factor: 11.151

2.  Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Authors:  Qian Jiang; Hong-ya Pan; Dong-xia Ye; Ping Zhang; Lai-ping Zhong; Zhi-yuan Zhang
Journal:  Tumour Biol       Date:  2010-06-08

3.  Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5.

Authors:  Hae-Wan Lee; Soo Kee Min; Young-Su Ju; Joohon Sung; Man Sup Lim; Dae Hyun Yang; Bong Hwa Lee
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

4.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

5.  PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.

Authors:  Victor D Fedorov; Maria Themeli; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-12-11       Impact factor: 17.956

6.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

7.  Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.

Authors:  Ahmad Al-Sukaini; Francis J Hornicek; Zachary S Peacock; Leonard B Kaban; Soldano Ferrone; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2017-07-19       Impact factor: 4.176

8.  Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Authors:  Chien-Chung Chang; Giuseppe Pirozzi; Shao-Hsuan Wen; I-Hsin Chung; Bau-Lin Chiu; Simona Errico; Monica Luongo; Maria Luisa Lombardi; Soldano Ferrone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

Review 9.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

10.  Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.

Authors:  Sara Michel; Michael Linnebacher; Joshua Alcaniz; Maike Voss; Rudolf Wagner; Wolfgang Dippold; Christina Becker; Magnus von Knebel Doeberitz; Soldano Ferrone; Matthias Kloor
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.